Publication Type:

Journal Article

Source:

Saudi Pharmaceutical Journal (2013)

URL:

http://www.scopus.com/inward/record.url?eid=2-s2.0-84878818823&partnerID=40&md5=bd3b6de5f5ca39200144a4bde7c2f4ca

Abstract:

Diabetes resulting from both genetic and lifestyle factors causes high insulin deficiency or its resistance. As hyperglycemia and decreased insulin secretion and/or its sensitivity appear to be the primary defects associated with diabetes, available treatments focus on reducing those defects. A novel approach of treatment is to target the incretin mimetic hormones, which are secreted by intestinal cells in response to food intake, provoking glucose-dependent insulin secretion from the pancreas. Efficacy and safety studies of dipetidyl peptidase inhibitors (DPP-IV), sitagliptin, vildagliptin and linagliptin provide similar improvements in HbA1c levels when compared with metformin, sulfonylureas or glitazones without contributing to weight gain and hypoglycemia. Caution is required when choosing the gliptin in people with renal or hepatic impairment and with a risk of pancreatitis. The glucagon like peptide (GLP-1) analogues Exenatide and Liraglutide also have positive impact on glycemic control especially when used as a combination therapy. Another upcoming approach is using sodium-glucose co transporter two inhibitors in kidney, by exploring pathophysiology of renal glucose re absorption in the proximal tubule. © 2013.

Notes:

cited By (since 1996)0; Article in Press

Cite this Research Publication

R. E. George and Joseph, S., “A review of newer treatment approaches for type-2 diabetes: Focusing safety and efficacy of incretin based therapy”, Saudi Pharmaceutical Journal, 2013.

207
PROGRAMS
OFFERED
5
AMRITA
CAMPUSES
15
CONSTITUENT
SCHOOLS
A
GRADE BY
NAAC, MHRD
9th
RANK(INDIA):
NIRF 2017
150+
INTERNATIONAL
PARTNERS